Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of TMC647055 + simeprevir with ritonavir, with or without GSK2336805 and with or without ribavirin, in chronic genotype 1 hepatitis C
2012-002555-42Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TMC-647055, simeprevir, GSK2336805, ritonavir and ribavirin in hepatitis C virus infection (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained virologic response 12 weeks after end of treatment. Started Jun 2012; status: completed.
02
Drugs
TMC-647055simeprevirGSK2336805ritonavirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-002555-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002555-42.